TEVA.NYSETeva Pharmaceutical Industries LTD

Form 4: Teva Pharmaceutical Executive Mark Sabag Reports Share Activity

Sentiment:

SEC Form 4 Filing

📋All filings for Teva Pharmaceutical Industries LTD
🔒Login to Follow

Mark Sabag, EVP of International Markets at Teva Pharmaceutical Industries, reports the vesting of restricted share units and subsequent ownership of ordinary shares.

Summary

  • On February 28, 2024, Mark Sabag, EVP of International Markets at Teva Pharmaceutical Industries, had 20,599 restricted share units vest.
  • These units converted into 20,599 ordinary shares.
  • Following the transaction, Sabag directly owns 342,281 ordinary shares.
  • The restricted share units were granted on February 28, 2020, and vested in four tranches.

Sentiment

Score: 5

Explanation: This is a neutral report on executive share transactions, with no inherent positive or negative implications for the company's performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies like Teva Pharmaceutical Industries.

Stakeholder Impact

  • The vesting of restricted share units may have a minor dilutive effect on existing shareholders.

Key Dates

DateDescription
February 28, 2020Restricted share units were granted.
February 28, 2021First tranche of restricted share units vested (20,598).
February 28, 2022Second tranche of restricted share units vested (20,598).
February 28, 2023Third tranche of restricted share units vested (20,598).
February 28, 2024Final tranche of restricted share units vested (20,599), and transaction date for this Form 4 filing.
March 01, 2024Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.